PITTSBURGH, Dec. 5, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration […]
Purchase Price Restructured to Hold Back $250 Million Contingent Upon Satisfaction of Certain Regulatory Conditions Mylan Board of Directors Sets April 11, 2014 as Date for Annual Meeting of Shareholders PITTSBURGH, Dec. 4, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides […]
– New, Interim Phase 3 Data Highlight Prolonged Half-Life of ELOCTATE™ and ALPROLIX™ in Young Children – – 10 Abstracts, Including Oral Presentation, Highlight Data from Hemophilia Research and Development Program – CAMBRIDGE, Mass.–(December 3, 2013)–Biogen Idec (NASDAQ: BIIB) will present new data from its hemophilia clinical development and research programs at the 55th Annual Meeting of the […]
A broad range of components for dose-efficient imaging systems, image processing workstations, and cancer treatment technologies, are on display at RSNA in Chicago CHICAGO, Dec. 2, 2013 /PRNewswire/ — Booth 4304 — A new lightweight wireless flat-panel digital X-ray image detector ideal for imaging extremities and for use in neonatal imaging systems is among the imaging components that […]
More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 2, 2013 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the launch of the largest multinational survey to investigate early […]
Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply payments Saphris is complementary to Forest’s existing CNS franchise and commercial infrastructure Agreement is expected to be immediately accretive to Forest NEW YORK — December […]
PITTSBURGH, Dec. 1, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL), one of the world’s leading pharmaceutical companies, and the Elton John AIDS Foundation (EJAF) today announced that they will give a combined $1 million to the Business Leadership Council for a Generation Born HIV Free (BLC) for the elimination of mother-to-child transmission (eMTCT) of HIV […]
Monaco 5 radiation therapy treatment planning system unites capabilities in a single system STOCKHOLM, November 27, 2013 – Monaco® 5, the latest version of Elekta’s Monaco treatment planning system has received 510(k) clearance from the US Food & Drug Administration, making it available for purchase and use in the United States. “Monaco 5 consolidates the […]
Results of Review¹ by Harley Street and University College Hospital London Presented in Online Edition of ‘Radiotherapy and Oncology’ (Green Journal) LONDON, Nov. 27, 2013 /PRNewswire/ — Treating early stage non-small-cell lung cancer (NSCLC) patients with advanced radiotherapy appears to be a viable alternative to surgery, according to researchers who carried out a retrospective comparative study sponsored […]
WHITEHOUSE STATION, N.J. November 26, 2013 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice […]